Altimmune (ALT) Financials

Altimmune, Inc. (ALT) reported diluted earnings per share of -$1.00 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Altimmune, Inc. (ALT) had EBITDA of -$94.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Altimmune, Inc. (ALT) had $43.8M in cash and equivalents against $34.3M in long-term debt.

Altimmune, Inc. (ALT) has a return on equity of -39.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Altimmune, Inc. (ALT) recorded an outflow of $67.5M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Altimmune, Inc. (ALT) recorded an outflow of $67.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Altimmune, Inc. (ALT) had $279.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Altimmune, Inc. (ALT) invested $11K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Altimmune, Inc. (ALT) invested $66.4M in research and development during fiscal year 2025.

Altimmune, Inc. (ALT) had 130M shares outstanding as of fiscal year 2025.

Altimmune, Inc. (ALT) had a current ratio of 18.55 as of fiscal year 2025, which is generally considered healthy.

Altimmune, Inc. (ALT) had a debt-to-equity ratio of 0.15 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Altimmune, Inc. (ALT) had a liabilities-to-equity ratio of 0.24 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Altimmune, Inc. (ALT) had a return on assets of -31.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Altimmune, Inc. (ALT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $398.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Altimmune, Inc. (ALT) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $41K revenue, FY2025). The market capitalization is $398.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Altimmune, Inc. (ALT) held $273.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $67.5M over that year. Dividing the one by the other, the reported balance equals about 49 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Altimmune, Inc. (ALT) has an Altman Z-Score of 1.11, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Altimmune, Inc. (ALT) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Altimmune, Inc. (ALT) reported a net loss of $88.1M while operations used $67.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Altimmune, Inc. (ALT) reported an operating loss of $94.5M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.